John and his team acted as the lead financial advisor and book runner for Adamis Pharmaceuticals, a specialty pharmaceutical company developing an EpiPen alternative for anaphylaxis and a number of respiratory drugs. Advisory services included guiding the company through the complex process of simultaneously marketing and closing a public offering and getting the company uplisted to a national stock exchange (Nasdaq Capital Market.)

Note: This work was performed prior to joining Stout.